Rituximab-induced acute thrombocytopenia: A case report and review of the literature

Jun Ho Yi, Seok Jin Kim, Hee Kyung Ahn, Su Jin Lee, Myung Hee Chang, Won Seog Kim

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Rituximab is a chimeric monoclonal antibody directed against the phosphoprotein CD20. Because of its efficacy and acceptable toxicity profile, rituximab is now commonly used for the treatment of CD20-positive B-cell malignancies, including B-cell non-Hodgkin's lymphoma. However, rituximab-induced acute thrombocytopenia is an extremely rare side effect. We report a case of acute thrombocytopenia occurring immediately after rituximab infusion in a mantle cell lymphoma patient with bone marrow involvement and massive splenomegaly. Although the mechanism of thrombocytopenia is still unclear, it is possible that tumor burden, bone marrow involvement, the presence of infusion-related symptoms, and mantle cell histology are related to this rare complication of rituximab therapy. Hence, rituximab should be used with caution in patients who have these factors, and clinicians must be aware of this rare, but serious, side effect.

Original languageEnglish
Pages (from-to)45-48
Number of pages4
JournalMedical Oncology
Issue number1
StatePublished - Mar 2009


  • Mantle cell lymphoma
  • Rituximab
  • Thrombocytopenia


Dive into the research topics of 'Rituximab-induced acute thrombocytopenia: A case report and review of the literature'. Together they form a unique fingerprint.

Cite this